Novelix Pharmaceuticals Ratios

Novelix Pharmaceuticals Ltd Ratios

The Novelix Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Novelix Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Novelix Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Novelix Pharmaceuticals Ltd (NSE: , BSE: 536565) is currently trading at ₹55.95, with a market capitalization of ₹978.16M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Novelix Pharmaceuticals Ltd remains a key stock for fundamental analysis using Novelix Pharmaceuticals Ltd Ratios.

Novelix Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Novelix Pharmaceuticals Ltd P/E ratio currently stands at 313.43, making it one of the most tracked metrics in Novelix Pharmaceuticals Ltd Ratios.

Historically, the Novelix Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 313.43
• 2023: 1340
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Novelix Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Novelix Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.51.

Historical P/B trend:

• 2024: 1.51
• 2023: 1.89
• 2022: 1.01
• 2021: 0.99

Novelix Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Novelix Pharmaceuticals Ltd P/S ratio currently stands at 0.86, an important part of Novelix Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.86
• 2023: 3.30
• 2022: 5.19
• 2021: 8.54

A stable or declining Novelix Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Novelix Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Novelix Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Novelix Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 77
• 2021: 12.14
• 2020: 3.44

The declining Novelix Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Novelix Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Novelix Pharmaceuticals Ltd EV currently stands at ₹257.98M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 257.98M
• 2023: 113.06M
• 2022: 45.15M
• 2021: 45.96M

Novelix Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Novelix Pharmaceuticals Ltd EV/EBITDA ratio is currently 162.23, a key metric in Novelix Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 162.23
• 2023: 0
• 2022: 0
• 2021: 0

Higher Novelix Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Novelix Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Novelix Pharmaceuticals Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Novelix Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Novelix Pharmaceuticals Ltd ROE currently stands at 0.68%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 0.68
• 2023: 0.14
• 2022: -0.82
• 2021: -22.12

Declining ROE indicates pressure on profitability.

Novelix Pharmaceuticals Ltd Ratios Analysis Summary

The Novelix Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Novelix Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Novelix Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.